Security
ACURA PHARMACEUTICALS INC Common Stock · ACUR
ACUROTCCommon stockCurrentCIK 786947Updated Nov 5, 2026
Name history
HALSEY DRUG CO INC/NEW · through Aug 16, 2004
ACUR price & chart
Loading TradingView…
OTC:ACUR on TradingView ↗In the news
No coverage from other publishers is available.
Recent filings
NT 10-Q filing
Entry into a Material Definitive Agreement · Completion of Acquisition or Disposition of Assets · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 1.01, 2.01, 2.03, 9.01
Entry into a Material Definitive Agreement · Completion of Acquisition or Disposition of Assets · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 1.01, 2.01, 2.03, 9.01
NT 10-Q filing
Entry into a Material Definitive Agreement · Completion of Acquisition or Disposition of Assets · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 1.01, 2.01, 2.03, 9.01
Show 5 more recent filings
Entry into a Material Definitive Agreement · Completion of Acquisition or Disposition of Assets · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 1.01, 2.01, 2.03, 9.01
Entry into a Material Definitive Agreement · Completion of Acquisition or Disposition of Assets · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 1.01, 2.01, 2.03, 9.01
NT 10-Q filing
Entry into a Material Definitive Agreement · Completion of Acquisition or Disposition of Assets · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 1.01, 2.01, 2.03, 9.01
NT 10-K filing
Financials
FY 2021 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 860,000Source | 1,736,000Source | 2,562,000Source | 2,152,000Source |
| Property, Plant and Equipment, NetUSD | 438,000Source | 484,000Source | 540,000Source | 606,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | — | — | 91,000Source |
| Assets, CurrentUSD | 372,000Source | 1,179,000Source | 1,178,000Source | 461,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 149,000Source | 139,000Source | 122,000Source | 166,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 682,000Source | 7,627,000Source | 7,303,000Source | 5,769,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 651,000Source | 216,000Source | 213,000Source | 210,000Source |
| Retained Earnings (Accumulated Deficit)USD | -390,083,000Source | -389,204,000Source | -387,996,000Source | -384,222,000Source |
| Stockholders' Equity Attributable to ParentUSD | 178,000Source | -5,891,000Source | -4,741,000Source | -3,617,000Source |
| Additional Paid in Capital, Common StockUSD | 389,610,000Source | 383,097,000Source | 383,042,000Source | 380,395,000Source |
| Liabilities and EquityUSD | 860,000Source | 1,736,000Source | 2,562,000Source | 2,152,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 515,000Source | 7,522,000Source | 1,074,000Source | 1,435,000Source |
| Accounts Payable, CurrentUSD | 192,000Source | 31,000Source | 237,000Source | 605,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 238,000Source | 631,000Source | 585,000Source | 596,000Source |
| Long-term Debt, Current MaturitiesUSD | 0Source | 6,000,000Source | — | 0Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | — | 6,000,000Source | — |
cash flow · annual statements
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -879,000Source | — | — | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 58,000Source | 36,000Source | 108,000Source | 218,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | 0Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | 0Source |
| Increase (Decrease) in Accounts PayableUSD | 161,000Source | -206,000Source | -368,000Source | 602,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -742,000Source | -719,000Source | -618,000Source | -3,908,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | 0Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 8,000Source | 2,000Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 394,000Source | 270,000Source | 1,389,000Source | 1,779,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 65,000Source | 413,000Source | 862,000Source | 91,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 0Source | — | — | 759,000Source |
| Income Taxes Paid, NetUSD | 0Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | — | 53,000Source | 138,000Source | 230,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | 66,000Source | 87,000Source |
| Amortization of Intangible AssetsUSD | 26,000Source | 69,000Source | 207,000Source | 207,000Source |
| DepreciationUSD | 47,000Source | 56,000Source | 66,000Source | 73,000Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | -1,000Source | 0Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | -2,600,000Source | 296,000Source |
| Impairment of Intangible Assets, Finite-livedUSD | 47,000Source | 668,000Source | — | — |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -879,000Source | -1,208,000Source | -3,774,000Source | -3,842,000Source |
| Nonoperating Income (Expense)USD | — | — | — | 73,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | 0Source |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | 4,350,000Source |
income statement · annual statements
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|
| Total RevenueUSD | 1,563,000Source | 3,570,000Source | 2,657,000Source | 410,000Source |
| Selling, General and Administrative ExpenseUSD | 1,253,000Source | 2,547,000Source | 1,877,000Source | 2,566,000Source |
| Operating Income (Loss)USD | -1,214,000Source | -758,000Source | -725,000Source | -3,915,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -879,000Source | -1,208,000Source | -3,774,000Source | -3,842,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -879,000Source | -1,208,000Source | -3,774,000Source | -3,842,000Source |
| Earnings Per Share, BasicUSD per share | -0.02Source | -0.04Source | -0.14Source | -0.18Source |
| Earnings Per Share, DilutedUSD per share | -0.02Source | -0.04Source | -0.14Source | -0.18Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 56,801,000Source | 32,320,000Source | 26,720,000Source | 21,146,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 56,801,000Source | 32,320,000Source | 26,720,000Source | 21,146,000Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 26,000Source | 69,000Source | 207,000Source | 207,000Source |
| Costs and ExpensesUSD | 2,777,000Source | 4,328,000Source | 3,382,000Source | 4,325,000Source |
| Interest ExpenseUSD | 200,000Source | 450,000Source | 449,000Source | 223,000Source |
| Interest Expense, DebtUSD | — | 450,000Source | 462,000Source | 395,000Source |
| Nonoperating Income (Expense)USD | — | — | — | 73,000Source |
| Research and Development ExpenseUSD | 1,524,000Source | 1,781,000Source | 1,505,000Source | 1,759,000Source |
Filing attachments
tm2628790d1_ex99-1.htm · 8-K · 2026-11-03
Exhibit 99.1 Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Date Principal Aggregated Principal ───────────────────────────────────────────────────────────────────────────────────────────────────────────────…
Read attachment ↗tm2627130d1_ex99-1.htm · 8-K · 2026-10-06
Exhibit 99.1 Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Date Principal Aggregated Principal ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── Original Secured Promissory Note 11/10/2022 $2,319,279 …
Read attachment ↗tm2623715d1_ex99-1.htm · 8-K · 2026-08-20
EX-99.1 2 tm2623715d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Date Principal Aggregated Principal ───────────────────────────────────────────────────────────────────…
Read attachment ↗tm2621293d1_ex99-1.htm · 8-K · 2026-07-24
EX-99.1 2 tm2621293d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Date Principal Aggregated Principal ──────────────────────────────────────────────────────────────────…
Read attachment ↗tm2619325d1_ex99-1.htm · 8-K · 2026-06-29
EX-99.1 2 tm2619325d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Date Principal Aggregated Principal ───────────────────────────────────────────────────────────────────…
Read attachment ↗tm2619325d1_ex99-2.htm · 8-K · 2026-06-29
EX-99.2 3 tm2619325d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 AMENDMENT #14 TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT This AMENDMENT #14 (this "Amendment") TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the "Agreement") dated June 28, 2019 between Acura Pharmaceuticals, Inc. ("Acura"), a New York corporation, having a place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, and Abuse Deterrent Pharma, LLC ("AD Pharma"), a Kentucky limited liability comp…
Read attachment ↗